Merck MRK announced that the phase III HYPERION study evaluating its pulmonary arterial hypertension (“PAH”) drug, Winrevair ...

Merck delivered a home run with its Phase 3 HYPERION trial, showcasing WINREVAIR’s prowess in battling pulmonary arterial ...

Long-term oxygen therapy (LTOT) is linked to reduced exacerbations and hospitalizations in COPD, ILD, and pulmonary hypertension.

Among patients with pulmonary arterial hypertension, once-daily treprostinil palmitil inhalation powder for 16 weeks reduced ...

Merck’s phase 3 HYPERION study of Winrevair meets primary endpoint in recently diagnosed adults with pulmonary arterial hypertension: Rahway, New Jersey Tuesday, June 24, 2025, ...

The projection represents a negative annual growth rate of 0.08%. The total number of diagnosed prevalent cases of pulmonary ...

A comprehensive new study from the Centers for Disease Control and Prevention’s National Center for Health Statistics shows that chronic health conditions are nearly universal among Americans age 85 ...

MORRISVILLE, N.C., June 23, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, ...

With patient enrollment now complete, topline results are expected early next year from a Phase 3 trial testing PAH treatment ...

In PAH, pulmonary rehabilitation referral and participation rates are low and are significantly affected by demographic and socioeconomic factors.

US pharma giant Merck & Co today announced positive top-line results from the Phase III HYPERION study evaluating Winrevair ...

Merck said that a phase-three study of its pulmonary arterial hypertension treatment met its primary endpoints.